INFORM GENOMICS ANNOUNCES COMPLETION OF ENROLLMENT IN FIRST PHASE OF DEVELOPMENT FOR OnPART™ PERSONALIZED MEDICINE PRODUCT

Boston, MA - September 7, 2012 - Inform Genomics, Inc., a private company focused on developing novel platforms of genomic based personalized medicine products for cancer supportive care and inflammatory diseases, today announced it has completed enrollment for the first phase of development for its lead platform product OnPART™. “Completing enrollment in this prospective study of 384 patients in a little more than 7 months is a tremendous accomplishment for our team and we look forward to receiving the top-line results in the near future,” said Dr. Ed Rubenstein, President & CEO of Inform Genomics.

The first phase of development for OnPART™ was conducted as a single center study at The West Clinic in Memphis Tennessee. The study included patients with breast, colorectal, lung and ovarian cancer who were treated with standard chemotherapy regimens including: dose-dense doxorubicin, cyclophosphamide and paclitaxel; oxaliplatin-based regimens for colorectal cancer; and carboplatin plus paclitaxel based regimens for lung and ovarian cancer. Patients were followed for a minimum of 2 cycles of chemotherapy- reporting symptoms of nausea and vomiting, mouth sores, diarrhea, fatigue, cognitive dysfunction and peripheral neuropathy using a validated questionnaire, the Patient Care Monitor©. Saliva was collected with an FDA approved kit for DNA samples, which will generate 2.5 million SNPs per patient.

The study will be analyzed using proprietary Bayesian Network algorithms that will identify the SNP networks associated with each symptom. The goal is to predict those patients who will develop moderate to severe symptoms. These symptoms can impair function, create inefficiencies in medical practice and are costly to patients and payers.

About OnPART™

OnPART™, Oncology Preferences And Risk of Toxicity, is Inform Genomics’ lead platform personalized medicine product for treatment decisions in patients who will receive chemotherapy for colorectal, breast, lung, or ovarian cancer. Based upon response rates and survival, more than one chemotherapy regimen may be considered appropriate care for patients with these common solid tumors, yet the regimens vary widely in their side-effect profiles. OnPART™ is being developed to assess genomic risk for common and often debilitating therapy-related side-effects, including fatigue, nausea and vomiting, diarrhea, oral mucositis, cognitive dysfunction and peripheral neuropathy. The product includes a differentiating factor in personalized medicine, quantifying patient concerns for side-effects, using a validated, copyrighted patient questionnaire (Preference Assessment Inventory©). OnPART™ is expected to provide valuable information for patients and medical oncologists to help clarify clinical choices and be commercially available in 2014.

About Cancer Supportive Care

Most patients with cancer receive supportive care as part of their multimodal anti-cancer therapy, regardless of cancer diagnosis, stage of disease, or treatment modality. Common symptoms associated with cancer or its treatments include fatigue, nausea and vomiting, diarrhea, oral mucositis, cognitive
dysfunction, and peripheral neuropathy. Some of these conditions are manageable with commercially available medications, while others are the focus of drug development programs. The development of these side-effects may interfere with ongoing anti-cancer treatment, impair patient functioning, negatively impact the patients’ quality of life, and may even increase the risk of mortality. Treatment of these side-effects also results in significant costs for payers and providers.

About Inform Genomics

Inform Genomics, Inc. is a private company focused on developing novel platforms of genomic based personalized medicine products for cancer supportive care and inflammatory diseases, including its lead platform product, OnPART™, designed to determine an individual’s risk of side-effects associated with chemotherapy regimens based on his or her individual genomic profile. The company’s business model leverages existing technology in conjunction with proprietary analytic methods for conducting genome-wide association studies. Product development programs will lead to commercial, single source laboratory tests consisting of single-nucleotide polymorphism (SNP) networks that determine the likelihood of individual patient clinical outcomes to drug therapies. The U.S. market opportunity for these differentiated products exceeds $2 billion annually. Inform Genomics is headquartered in Boston, Massachusetts. For more information, please visit www.informgenomics.com.

Contact:
Bill Brown, Chief Financial Officer
bbrown@informgenomics.com